Гилтеритиниб в терапии впервые диагностированного FLT3-позитивного варианта острого миелоидного лейкоза: от биологии к клинической практике (опыт МРНЦ им. А.Ф. Цыба)

Даниил Артурович Манаенков; Н. А. Фалалеева; В. А. Шуваев; А. В. Поденок; А. В. Жердева; Е. Н. Бабич

doi:10.21320/2500-2139-2026-19-4-434-442

Gilteritinib for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: from Biology to Clinical Practice (Experience of the AF Tsyb Medical Radiological Research Center)

Daniil Arturovich Manaenkov, N.A. Falaleeva, V.A. Shuvaev, A.V. Podenok, A.V. Zherdeva, E.N. Babich,

DOI:

https://doi.org/10.21320/2500-2139-2026-19-4-434-442

Abstract Authors References

Mutations in the FLT3 gene, predominantly of the FLT3-ITD type, are ubiquitous molecular genetic abnormalities associated with unfavorable prognosis in acute myeloid leukemias (AML). In recent years, new FLT3-targeted inhibitors have been actively introduced into clinical practice; their combination with the standard chemotherapy regimens yields the improvement of treatment outcomes in this patient cohort. This paper reports the personal clinical experience and the outcomes of treating three patients with newly diagnosed AML and the FLT3-ITD mutation. All patients received “7+3” induction therapy combined with gilteritinib followed by high-dose cytarabine (HiDAC) and gilteritinib consolidation. Complete remission with incomplete peripheral blood recovery was achieved in all patients. In two patients, MRD negativity and eradication of the FLT3 clone were reported, which allowed to perform allogeneic hematopoietic stem cell transplantation (allo-HSCT), haploidentical and from unrelated donor, respectively. Both patients sustain remission and 100 % donor chimerism. The third patient, despite his deep response, could not receive transplantation due to the lack of an available donor, which resulted in an early disease relapse. In one case, the treatment was complicated by infections and hemophagocytic lymphohistiocytosis, which had been successfully controlled by Janus kinase inhibitor (ruxolitinib). Thus, the integration of gilteritinib into the first-line induction and consolidation regimens can be regarded as an effective strategy for the treatment of AML with FLT3 mutation, as it provides deep (MRD-negative) response. The key factor in the long-term control of the disease is allo-HSCT during the first complete remission.

Daniil Arturovich Manaenkov AF Tsyb Medical Radiological Research Center, branch of the NMRC of Radiology, 4 Koroleva ul., Obninsk, Kaluga Region, Russian Federation, 249036 https://orcid.org/0009-0007-9269-7405 (unauthenticated)
N.A. Falaleeva AF Tsyb Medical Radiological Research Center, branch of the NMRC of Radiology, 4 Koroleva ul., Obninsk, Kaluga Region, Russian Federation, 249036 ; Obninsk Institute for Nuclear Power Engineering, branch of the MIFI National Research Nuclear University, 1 Studgorodok ter., Obninsk, Kaluga Region, Russian Federation, 249039 https://orcid.org/0000-0002-0023-4216 (unauthenticated)
V.A. Shuvaev AF Tsyb Medical Radiological Research Center, branch of the NMRC of Radiology, 4 Koroleva ul., Obninsk, Kaluga Region, Russian Federation, 249036 ; Obninsk Institute for Nuclear Power Engineering, branch of the MIFI National Research Nuclear University, 1 Studgorodok ter., Obninsk, Kaluga Region, Russian Federation, 249039 ; Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993 https://orcid.org/0000-0003-3536-0770 (unauthenticated)
A.V. Podenok AF Tsyb Medical Radiological Research Center, branch of the NMRC of Radiology, 4 Koroleva ul., Obninsk, Kaluga Region, Russian Federation, 249036 https://orcid.org/0009-0007-0829-871X (unauthenticated)
A.V. Zherdeva Kaluga Regional Clinical Hospital, 1 Vishnevskogo ul., Kaluga, Russian Federation, 248007 https://orcid.org/0009-0001-5574-1661 (unauthenticated)
E.N. Babich Yugry District Clinical Hospital, 40 Kalinina ul., Khanty-Mansiisk, Russian Federation, 628011 https://orcid.org/0009-0002-8815-0099 (unauthenticated)

Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29. doi: 10.1186/s13045-023-01424-6. DOI: https://doi.org/10.1186/s13045-023-01424-6
Negotei C, Colita A, Mitu I, et al. A review of FLT3 kinase inhibitors in AML. J Clin Med. 2023;12(20):6429. doi: 10.3390/jcm12206429. DOI: https://doi.org/10.3390/jcm12206429
Arai Y, Chi S, Minami Y, et al. FLT3-targeted treatment for acute myeloid leukemia. Int J Hematol. 2022;116(3):351–63. doi: 10.1007/s12185-022-03374-0. DOI: https://doi.org/10.1007/s12185-022-03374-0
Bivona C, Elsey R, Williams C. Targeting FLT3 and KIT mutations in AML with midostaurin: implications for clinicians and pharmacists. J Hematol Oncol Pharm. 2019;9(3):150–8.
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40. doi: 10.1056/NEJMoa1902688. DOI: https://doi.org/10.1056/NEJMoa1902688
ClinicalTrials.gov. Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML). Available from: https://clinicaltrials.gov/study/NCT03836209?tab=study (accessed 15.08.2026).
Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020;10:612880. doi: 10.3389/fonc.2020.612880. DOI: https://doi.org/10.3389/fonc.2020.612880
ClinicalTrials.gov. A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18). Available from: https://clinicaltrials.gov/study/NCT04027309 (accessed 15.08.2026).
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77. doi: 10.1182/blood.2022016867. DOI: https://doi.org/10.1182/blood.2022016867
Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929. doi: 10.1002/pbc.27929. DOI: https://doi.org/10.1002/pbc.27929
Yildiz H, Van Den Neste E, Defour JP, et al. Adult haemophagocytic lymphohistiocytosis: a review. QJM. 2022;115(4):205–13. doi: 10.1093/qjmed/hcaa011. DOI: https://doi.org/10.1093/qjmed/hcaa011
Манаенков Д.А., Галицына А.Б., Фалалеева Н.А. и др. Гемофагоцитарный лимфогистиоцитоз: обзор литературы и клинический случай. MD-Onco. 2024;4(4):100–6. doi: 10.17650/2782-3202-2024-4-4-100-106. [Manaenkov D.A., Galitsyna A.B., Falaleeva N.A., et al. Hemophagocytic lymphohistiocytosis: literature review and clinical case. MD-Onco. 2024;4(4):100–6. doi: 10.17650/2782-3202-2024-4-4-100-106. (In Russ)] DOI: https://doi.org/10.17650/2782-3202-2024-4-4-100-106
Kröger N, Gribben J, Chabannon C, et al. (eds). The EBMT/EHA CAR-T Cell Handbook. Cham: Springer International Publishing; 2022. doi: 10.1007/978-3-030-94353-0. DOI: https://doi.org/10.1007/978-3-030-94353-0
Moiseev IS. PTCy and ruxolitinib vs PTCy, tacrolimus and MMF in MUD and haploidentical HSCT. ClinicalTrials.gov, 2020. Available from: https://www.clinicaltrials.gov/study/NCT04669210 (accessed 17.02.2026).
Penack O. Prevention is better than cure. Blood. 2025;145(20):2236–7. doi: 10.1182/blood.2025029023. DOI: https://doi.org/10.1182/blood.2025029023
DeFilipp Z, Kim HT, Knight LW, et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood. 2025;145(20):2312–6. doi: 10.1182/blood.2024028005. DOI: https://doi.org/10.1182/blood.2024028005
Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol. 2024;42(15):1766–75. doi: 10.1200/JCO.23.02474. DOI: https://doi.org/10.1200/JCO.23.02474
Pratz KW, Cherry M, Altman JK, et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML. J Clin Oncol. 2023;41(26):4236–46. doi: 10.1200/JCO.22.02721. DOI: https://doi.org/10.1200/JCO.22.02721
Stenger M. Incorporation of gilteritinib into induction and consolidation chemotherapy and as maintenance therapy in newly diagnosed patients with AML. The ASCO Post. 2023. Available from: https://ascopost.com/issues/august-10-2023/incorporation-of-gilteritinib-into-induction-and-consolidation-chemotherapy-and-as-maintenance-therapy-in-newly-diagnosed-patients-with-aml/ (accessed 17.02.2026).
Pratz KW, Cherry M, Altman JK, et al. Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood. 2018;132(Suppl 1):564. doi: 10.1182/blood-2018-99-110975. DOI: https://doi.org/10.1182/blood-2018-99-110975
Wang ES, Altman JK, Minden MD, et al. Impact of FLT3 mutation clearance after front-line treatment with gilteritinib plus azacitidine, or gilteritinib or azacitidine alone in patients with newly diagnosed AML: results from the phase 2/3 LACEWING trial. Blood. 2021;138(Suppl 1):3445. doi: 10.1182/blood-2021-145362. DOI: https://doi.org/10.1182/blood-2021-145362
Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845–57. doi: 10.1182/blood.2021014586. DOI: https://doi.org/10.1182/blood.2021014586
Magee GH, Grunwald MR. Updates on therapy options in fit and unfit patients with newly diagnosed AML. Curr Treat Options Oncol. 2025;26(9):829–40. doi: 10.1007/s11864-025-01351-3. DOI: https://doi.org/10.1007/s11864-025-01351-3
Numan Y, Abdel Rahman Z, Grenet J, et al. Gilteritinib clinical activity in relapsed/refractory FLT3-mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022;97(3):322–8. doi: 10.1002/ajh.26447. DOI: https://doi.org/10.1002/ajh.26447
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64. doi: 10.1056/NEJMoa1614359. DOI: https://doi.org/10.1056/NEJMoa1614359
Voso MT, Larson RA, Jones D, et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subgroup analysis from the RATIFY trial. Blood Adv. 2020;4(19):4945–54. doi: 10.1182/bloodadvances.2020002904. DOI: https://doi.org/10.1182/bloodadvances.2020002904
Oñate G, Pratcorona M, Garrido A, et al. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer J. 2023;13(1):69. doi: 10.1038/s41408-023-00839-1. DOI: https://doi.org/10.1038/s41408-023-00839-1
Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441–9. doi: 10.1182/blood-2014-05-578070. DOI: https://doi.org/10.1182/blood-2014-05-578070
Oran B, Cortes J, Beitinjaneh A, et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant. 2016;22(7):1218–26. doi: 10.1016/j.bbmt.2016.03.027. DOI: https://doi.org/10.1016/j.bbmt.2016.03.027
Ciurea SO. Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia in first complete remission: does age really matter? Haematologica. 2018;103(2):191–3. doi: 10.3324/haematol.2017.186346. DOI: https://doi.org/10.3324/haematol.2017.186346
Wang J, Jiang B, Li J, et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 2024;38(11):2410–8. doi: 10.1038/s41375-024-02382-9. DOI: https://doi.org/10.1038/s41375-024-02382-9

Keywords:

acute myeloid leukemia, mutation in the FLT3 gene, gilteritinib, allogeneic hematopoietic stem cell transplantation

License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

Daniil Arturovich Manaenkov, , AF Tsyb Medical Radiological Research Center, branch of the NMRC of Radiology, 4 Koroleva ul., Obninsk, Kaluga Region, Russian Federation, 249036, e-mail: manaenkov.00@inbox.ru

Downloads

PDF_2026-19-4-434-442 (Russian)

Published

01.10.2026

Issue

Vol. 19 No. 4 (2026)

MYELOID TUMORS

How to Cite

Manaenkov D.A., Falaleeva N.A., Shuvaev V.A., Podenok A.V., Zherdeva A.V., Babich E.N. Gilteritinib for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: from Biology to Clinical Practice (Experience of the AF Tsyb Medical Radiological Research Center). Clinical Oncohematology. Basic Research and Clinical Practice. 2026;19(4):434–442. doi:10.21320/2500-2139-2026-19-4-434-442.

Download Citation

Most read articles by the same author(s)

Anait Levonovna Melikyan, I.N. Subortseva, A.M. Kovrigina, V.A. Shuvaev, E.V. Morozova, E.G. Lomaia, V.V. Baykov, O.Yu. Vinogradova, S.V. Gritsaev, T.I. Ionova, P.I. Kuznetsova, L.A. Kuzmina, I.S. Martynkevich, T.A. Mitina, E.S. Polushkina, T.I. Pospelova, M.A. Sokolova, A.B. Sudarikov, M.M. Tanashyan, A.G. Turkina, Yu.V. Shatokhin, R.G. Shmakov, E.N. Parovichnikova, National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 17 No. 3 (2024)
V.O. Sarzhevskii, Aisel Akifovna Mamedova, N.E. Mochkin, E.A. Demina, A.A. Spornik, A.A. Samoilova, V.S. Bogatyrev, A.A. Rukavitsyn, E.G. Smirnova, N.S. Shorokhov, A.E. Bannikova, V.Ya. Melnichenko, N.B. Mikhailova, E.S. Borzenkova, L.V. Stelmakh, Yu.R. Zalyalov, A.A. Semenova, G.S. Tumyan, M.A. Danilova, O.A. Konova, N.A. Falaleeva, AYu Terekhova, M.A. Vernyuk, A.M. Chervontseva, L.S. Khairullina, A.A. Maslov, I.B. Lysenko, Yu.A. Alekseeva, E.S. Pavlyuchenko, A.A. Mirsaitov, A.A. Zverkova, I.V. Ishmatova, S.A. Volchenkov, M.S. Motalkina, I.S. Zyuzgin, Nivo-DHAP Combined with Subsequent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Trial (ClinicalTrials.gov, NCT04091490) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 17 No. 1 (2024)
Anait Levonovna Melikyan, A.M. Kovrigina, I.N. Subortseva, V.A Shuvaev, E.V. Morozova, E.G. Lomaia, B.V. Afanasyev, T.A. Ageeva, V.V. Baikov, O.Yu. Vinogradova, S.V. Gritsaev, A.Yu. Zaritskey, T.I. Ionova, K.D. Kaplanov, I.S. Martynkevich, T.A. Mitina, E.S. Polushkina, T.I. Pospelova, M.A. Sokolova, A.B. Sudarikov, A.G. Turkina, Yu.V. Shatokhin, R.G. Shmakov, V.G. Savchenko, National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 14 No. 2 (2021)
T.I. Ionova, E.A. Andreevskaya, E.N. Babich, N.B. Bulieva, O.Yu. Vinogradova, E.M. Volodicheva, S.V. Voloshin, N.N. Glonina, S.K. Dubov, N.B. Esef’eva, A.Yu. Zaritskey, E.E. Zinina, M.O. Ivanova, T.Yu. Klitochenko, A.V. Kopylova, A.D. Kulagin, G.B. Kuchma, O.Yu. Li, E.G. Lomaia, A.L. Melikyan, V.Ya. Melnichenko, S.N. Menshakova, N.V. Minaeva, T.A. Mitina, E.V. Morozova, Tatyana Pavlovna Nikitina, O.E. Ochirova, A.S. Polyakov, T.I. Pospelova, A.V. Proidakov, O.A. Rukavitsyn, G.Sh. Safuanova, I.N. Subortseva, M.S. Fominykh, M.V. Frolova, T.V. Shelekhova, D.G. Sherstnev, T.V. Shneider, V.A. Shuvaev, Z.K. Abdulkhalikova, L.V. Anchukova, I.A. Apanaskevich, A.N. Arnautova, M.V. Barabanshchikova, N.V. Berlina, A.P. Bityukov, E.A. Gilyazitdinova, V.I. Gilmanshina, E.K. Egorova, E.V. Efremova, E.B. Zhalsanova, E.N. Kabanova, O.B. Kalashnikova, A.E. Kersilova, T.I. Kolosheinova, P.M. Kondratovskii, E.V. Koroleva, A.N. Kotelnikova, N.A. Lazareva, N.S. Lazorko, E.V. Lyyurova, A.S. Lyamkina, Yu.N. Maslova, E.S. Mileeva, N.E. Mochkin, E.K. Nekhai, Ya.A. Noskov, E.S. Osipova, M.M. Pankrashkina, E.V. Potanina, O.D. Rudenko, T.Yu. Rozhenkova, E.I. Sbityakova, N.T. Siordiya, A.V. Talko, E.I. Usacheva, Yu.B. Chernykh, T.V. Chitanava, K.S. Shashkina, D.I. Shikhbabaeva, K.S. Yurovskaya, Current Quality-of-Life Aspects in Patients with Classical Ph-Negative Myeloproliferative Neoplasms in the Russian Federation: Results and Discussion of the National Observational Program MPN-QoL-2020 , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 15 No. 2 (2022)
T.V. Shelekhova, J. Kumar, S.J. Apte, Iu.S. Osipov, E.N. Misyurina, V.A. Doronin, T.S. Konstantinova, B.A. Bakirov, A.V. Proidakov, A.L. Uss, M. Kumar, E.V. Martynova, N.G. Chernova, M.A. Khokhar, A.D. Garifullin, C.R. Ross, S.L. Cyriac, S.V. Voloshin, M.A. Ulyanova, N.A. Falaleeva, N.A. Katin, D.V. Kirtbaya, M.O. Kiseleva, E.Yu. Komarceva, A.A. Myasnikov, D.K. Novik, M. Shabbir-Moosajee, S.V. Samarina, V.V. Denisova, G.N. Khusainova, T.K. Dolai, B. Bagchi, I.S. Zyuzgin, I.S. Moiseev, T.I. Pospelova, A.A. Semenova, M.A. Novikova, I.L. Davydkin, M.V. Kosinova, A.M. Pavlova, N. Sidharthan, H. Mukhopadhyay, A. Wahid, Q.M. Buttar, Yu.N. Linkova, A.V. Zinkina-Orikhan, Svyatoslav Vladimirovich Nechaev, A.S. Shadrina, A.A. Lutckii, D.O. Liaptseva, Results of a Double-Blind Prospective Comparative Randomized Phase 3 Clinical Trial of the Efficacy and Safety of BCD-264 and Darzalex as Monotherapy for Relapsed/Refractory Multiple Myeloma (BCD-264-2/DARVIVA) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 19 No. 2 (2026)
Liudmila Valerevna Fedorova, N.B. Mikhailova, K.V. Lepik, A.M. Chekalov, O.G. Smykova, V.V. Markelov, G.S. Tumyan, A.A. Semenova, A.V. Arakelyan, L.S. Butaev, Iu.A. Oleinik, V.V. Ptushkin, Ya.K. Mangasarova, A.U. Magomedova, E.S. Gitelzon, N.G. Gabeeva, D.A. Koroleva, A.K. Smolianinova, E.E. Zvonkov, Iu.S. Osipov, N.V. Stepanova, T.V. Krinitsina, Yu.I. Podmankova, G.N. Khusainova, L.F. Mukharlyamova, O.R. Smirnova, I.V. Ishmatova, A.A. Zverkova, S.S. Elkhova, S.A. Volchenkov, I.S. Zyuzgin, D.D. Ivanova, E.A. Baryakh, E.N. Misyurina, P.A. Zeinalova, F.M. Abbasbeyli, O.L. Timofeeva, Yu.E. Ryabukhina, M.A. Ulyanova, V.V. Basmanova, T.N. Tsyganok, V.Yu. Kimaikina, S.V. Samarina, E.V. Zubkova, S.V. Ovanesyan, A.I. Iskhakova, A.Yu. Kuvshinov, A.A. Kuzyaeva, G.K. Isaeva, M.I. Andrievskikh, O.Yu. Arzhanukhina, T.V. Shelekhova, I.V. Morozova, P.V. Makarovskaya, O.S. Samoilova, I.V. Vasileva, A.Yu. Terekhova, N.A. Falaleeva, V.A. Shuvaev, S.V. Vlasova, V.A. Lapin, V.I. Bakhtina, A.D. Kulagin, Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 19 No. 2 (2026)
A.G. Turkina, O. Yu. Vinogradova, E.G. Lomaia, B.A. Bakirov, N.M. Kalimulina, T.V. Shelekhova, I.L. Davydkin, T.I. Pospelova, O.A. Shukhov, E.Yu. Chelysheva, V.A. Shuvaev, S. Lavana, V. Khushoo, S. Apte, T.K. Dolai, R.K. Sahoo, Germes Grigorevich Chilov, Phase 3 Clinical Trial of 300 mg Vamotinib Directly Compared with High-Dose Imatinib in Chronic Myeloid Leukemia Patients in Chronic Phase with Failure of Standard-Dose Imatinib: Interim Analysis , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 19 No. 1 (2026)
Artem Andreevich Vovchenko, N.A. Falaleeva, A.A. Danilenko, A.Yu. Terekhova, M.M. Khodzhibekova, A.M. Chelmakov, A.G. Zamotina, A.S. Dikova, S.V. Ruchkova, Yu.V. Sinitsyna, V.Yu. Kovalskaya, A.N. Perepelitsyna, A.N. Balashova, D.A. Manaenkov, S.A. Ivanov, The Value of Combined PET/CT in Diffuse Large B-Cell Lymphoma: Historical Background, Evolution of Views, and Current Opportunities of the Method (Literature Review) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 17 No. 1 (2024)
A.L. Melikyan, A.G. Turkina, Irina Nikolaevna Subortseva, E.Yu. Chelysheva, A.M. Kovrigina, V.A. Shuvaev, V.V. Baikov, O.Yu. Vinogradova, S.M. Kulikov, A.N. Petrova, A.V. Bykova, A.-P.A. Poshivai, Yu.Yu. Vlasova, M.M. Chukavina, O.D. Serdyuk, K.V. Naumova, N.T. Siordiya, N.S. Lazorko, R.V. Grozov, E.I. Mullo, A.S. Maksimova, O.M. Senderova, O.V. Kanya, M.S. Fominykh, D.I. Shikhbabaeva, E.A. Belyakova, I.S. Martynkevich, L.B. Polushkina, M.N. Zenina, E.V. Efremova, V.I. Rugal, L.P. Papayan, N.E. Korsakova, O.Yu. Matvienko, E.B. Syrtseva, S.V. Gappoev, M.V. Barabanshchikova, M.O. Ivanova, K.D. Kaplanov, E.S. Rogova, K.B. Trizna, A.S. Zhevnyak, O.E. Ochirova, A.A. Shakhaeva, A.S. Lyamkina, I.P. Mikhno, Yu.B. Chernykh, T.V. Chudanova, I.N. Kontievskii, N.N. Glonina, M.V. Burundukova, Materials of the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” (March 15–16, 2019; National Research Center for Hematology, Moscow) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 13 No. 2 (2020)
Alena Yurevna Terekhova, N.A. Falaleeva, A.B. Galitsyna, A.M. Chelmakov, A.A. Vovchenko, N.A. Riabikina, A.A. Danilenko, T. I. Bogatyreva, Treatment Outcomes in Primary Mediastinal Large B-Cell Lymphoma. Experience of the AF Tsyb Medical Radiological Research Center (Obninsk) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 17 No. 3 (2024)